Valuation: Scancell Holdings plc

Market Cap 114M 151M 134M 125M 215M 14.56B 216M 1.5B 589M 7.41B 565M 553M 23.79B P/E 2026 *
-6.28x
P/E 2027 * -3.79x
Enterprise Value 124M 164M 147M 137M 234M 15.9B 236M 1.64B 642M 8.09B 616M 604M 25.97B EV / Sales 2026 *
99.5x
EV / Sales 2027 * 56.2x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day-0.53%
1 month-4.08%
3 months-36.27%
6 months-18.26%
Current year-5.05%
1 week 9.3
Extreme 9.3
9.6
1 month 9.3
Extreme 9.3
10.55
Current year 9.3
Extreme 9.3
29.5
1 year 9.1
Extreme 9.1
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 69 2021-07-27
Chief Executive Officer 64 2024-11-17
Director of Finance/CFO 50 2026-04-23
Director TitleAgeSince
Director/Board Member 69 2010-11-16
Director/Board Member 74 2019-10-22
Director/Board Member 64 2020-09-23
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
8/8/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
8/4/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%0.00%-3.59%-36.27% 152M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-1.16%+23.36%+79.34% 58.81B
+0.17%-1.16%+3.59%+34.55% 48.45B
+0.50%-1.77%+331.24%+702.20% 42.84B
-0.72%-4.04%+25.90%+29.94% 42.79B
+0.34%-0.34%+5.66%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-0.50%-3.37%-9.42%-14.35% 24.05B
Average +0.16%-0.28%+47.03%+107.79% 39.44B
Weighted average by Cap. +0.69%-0.54%+55.48%+130.14%

Financials

2026 *2027 *
Net sales 1.25M 1.65M 1.47M 1.38M 2.35M 160M 2.37M 16.51M 6.46M 81.28M 6.2M 6.07M 261M 2.31M 3.05M 2.72M 2.54M 4.35M 295M 4.38M 30.48M 11.92M 150M 11.44M 11.2M 482M
Net income -19.23M -25.42M -22.68M -21.17M -36.23M -2.46B -36.51M -254M -99.34M -1.25B -95.34M -93.36M -4.02B -27.94M -36.93M -32.95M -30.75M -52.64M -3.57B -53.04M -369M -144M -1.82B -139M -136M -5.83B
Net Debt 10.42M 13.77M 12.28M 11.46M 19.62M 1.33B 19.77M 138M 53.8M 677M 51.63M 50.56M 2.17B 15.79M 20.86M 18.62M 17.37M 29.74M 2.02B 29.96M 208M 81.53M 1.03B 78.25M 76.62M 3.3B
Projected Income Statement - Annual - Scancell Holdings plc
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
26-10-07 GBX 9.400 -0.53% 1,306,032
26-10-06 GBX 9.450 +0.53% 4,319,405
26-10-05 GBX 9.400 -1.05% 924,430
26-10-02 GBX 9.500 +1.60% 1,881,946
26-10-01 GBX 9.350 -0.53% 1,350,349
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Scancell Holdings plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0940GBP
Average target price
0.2550GBP
Spread / Average Target
+171.28%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Scancell Holdings plc
  1. Stock Market
  2. Stocks
  3. SCLP Stock